STOCK TITAN
  1. Home
  2. Sec-filings
  3. ASBP
  4. [8-K] Aspire Biopharma Holdings, Inc. Reports Material Event

Aspire Biopharma (NASDAQ: ASBP) reports 2026 special meeting vote results

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Aspire Biopharma Holdings, Inc. held a Special Meeting of Stockholders on April 10, 2026, where a quorum of stockholders voted on several proposals. The 8-K reports that all matters presented at the meeting were approved based on the tabulated voting results.

The disclosed proposals received votes in favor ranging from 1,466,141 to 2,096,356, with varying levels of opposition, abstentions, and broker non-votes. The filing confirms the outcomes of these stockholder votes and is signed by Chief Executive Officer Kraig Higginson.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Top proposal votes for 2,096,356 votes Highest votes for any proposal at April 10, 2026 meeting
Top proposal votes against 582,185 votes Opposition on highest-supported proposal
Top proposal abstentions 12,852 votes Abstain votes on highest-supported proposal
Proposal votes for (example) 1,466,141 votes Votes for on one additional proposal with broker non-votes
Broker non-votes (example) 1,012,844 votes Broker non-votes recorded on two proposals
Other proposal votes for 1,925,368 votes Votes for on another proposal at the meeting
Other proposal votes against 551,855 votes Opposition on another proposal at the meeting
Special Meeting of Stockholders financial
"On April 10, 2026, at the Special Meeting of Stockholders (the “Meeting”)"
A special meeting of stockholders is an unscheduled gathering called to let shareholders vote on specific, often urgent company decisions—like mergers, major asset sales, changes to the board, or amendments to governing rules. Think of it as an emergency town hall where owners cast ballots in person or by mail/online; outcomes can materially change a company’s strategy, control or value, so investors pay close attention and may need to vote or adjust holdings accordingly.
broker non-votes financial
"Votes For | Votes Against | Votes Abstain | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
Emerging growth company regulatory
"Emerging growth company Item 5.07 Submission of Matters"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Common Stock, par value $0.0001 per share financial
"Common Stock, par value $0.0001 per share | ASBP"
Inline XBRL technical
"Cover Page Interactive Data File (embedded with the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What did Aspire Biopharma (ASBP) disclose in this 8-K filing?
Aspire Biopharma reported the voting results from its April 10, 2026 Special Meeting of Stockholders. Multiple proposals were approved, with votes in favor ranging from 1,466,141 to 2,096,356, alongside recorded votes against, abstentions, and broker non-votes.

How many Aspire Biopharma shares voted for the highest-supported proposal?
The highest-supported proposal received 2,096,356 votes for, 582,185 votes against, and 12,852 abstentions, with zero broker non-votes. These figures show substantial support among shares present at the April 10, 2026 Special Meeting of Stockholders.

What are broker non-votes in Aspire Biopharma’s 2026 special meeting results?
Broker non-votes are shares held by brokers that were not voted on certain proposals. In Aspire Biopharma’s April 10, 2026 results, some proposals show broker non-votes up to 1,012,844 shares, indicating brokers did not vote those shares on specific items.

Who signed Aspire Biopharma’s April 2026 8-K about stockholder voting?
The 8-K summarizing the April 10, 2026 Special Meeting voting results was signed on behalf of Aspire Biopharma Holdings, Inc. by Chief Executive Officer Kraig Higginson, confirming the company’s authorization of the reported stockholder vote outcomes.

On which exchange is Aspire Biopharma (ASBP) listed and what securities trade?
Aspire Biopharma’s common stock, par value $0.0001 per share, trades under the symbol ASBP on The Nasdaq Stock Market LLC. Warrants, each exercisable for one share of common stock, trade on Nasdaq under the symbol ASBPW.

What voting range did other Aspire Biopharma proposals receive at the meeting?
Other proposals received votes for between 1,466,141 and 1,925,368 shares, with votes against up to 551,855 and abstentions up to 11,679. Broker non-votes ranged from 0 to 1,012,844, showing varied turnout across the different agenda items.
false 0001847345 0001847345 2026-04-10 2026-04-10 0001847345 ASBP:CommonStockParValue0.0001PerShareMember 2026-04-10 2026-04-10 0001847345 ASBP:WarrantsEachExercisableForOneShareOfCommonStockMember 2026-04-10 2026-04-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 10, 2026

 

ASPIRE BIOPHARMA HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41293   33-3467744

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

23150 Fashion Drive, Suite 230

Estero, Florida

   33928
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (908) 987-3002

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ASBP   The Nasdaq Stock Market LLC
Warrants, each exercisable for one share of common stock   ASBPW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On April 10, 2026, at the Special Meeting of Stockholders (the “Meeting”) of Aspire Biopharma Holdings, Inc. (the “Company”), the Company’s stockholders constituting a quorum voted on, and approved, the matters described below.

 

1. To approve one or more amendments to our Charter to effect (a) one or more reverse splits of the Company’s issued and outstanding shares of capital stock at a ratio of 1-for-5 to 1-for-500, in the aggregate, with the exact ratio within such range to be determined by the Board of Directors of the Company at its discretion (the “Reverse Split”), and (b) the reverse stock split, if at all, within one year of the date the proposal is approved by stockholders, each subject to the Board’s authority to abandon such amendments (the “Reverse Stock Split Proposal”). The number of shares that voted for, against, and withheld from voting for this Reverse Stock Split Proposal is summarized in the table below:

 

Votes For  Votes Against  Votes Abstain  Broker Non-Votes
          
2,096,356  582,185  12,852  0

 

2. To authorize, for purposes of complying with Nasdaq listing rule 5635(d), (i) the issuance of the shares of common stock of the Company issuable upon conversion of the Series A Convertible Preferred Stock (the “Conversion Shares”), including the issuance of all of the Conversion Shares in excess of 19.99% of the issued and outstanding Common Stock on February 6, 2026, and (ii) the floor price (the “Floor Price”) at which the Series A Preferred Stock may be converted, equal to 20% of the Minimum Price (as such term is defined by the rules and regulations of the Nasdaq Stock Market LLC, Rule 5635(d)(1)(A) (the “Series A Preferred Issuance Proposal”). The number of shares that voted for, against, and withheld from voting for this Series A Preferred Issuance Proposal is summarized in the table below:

 

Votes For  Votes Against  Votes Abstain  Broker Non-Votes
          
1,466,141  203,756  8,652  1,012,844

 

3. To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of 19.99% or more of our issued and outstanding common stock pursuant to that certain Purchase Agreement (the “ELOC Agreement”) between the Company and Arena Business Solutions Global SPC II, Ltd., dated November 11, 2025 (the “ELOC Issuance Proposal”. The number of shares that voted for, against, and withheld from voting for this ELOC Issuance Proposal is summarized in the table below:

 

Votes For  Votes Against  Votes Abstain  Broker Non-Votes
          
1,469,985  203,926  4,638  1,012,844

 

4. To approve an amendment to the articles of incorporation to increase the authorized shares of common stock from 490,000,000 shares to 700,000,000 shares (the “Authorized Common Stock Increase Proposal”). The number of shares that voted for, against, and withheld from voting for this Authorized Common Stock Increase Proposal is summarized in the table below:

 

Votes For  Votes Against  Votes Abstain  Broker Non-Votes
          
1,925,368  524,501  7,403  234,122

 

5. To approve one or more adjournments of the Special Meeting, if necessary or appropriate, to solicit additional proxies in favor of the Reverse Stock Split Proposal, Series A Preferred Issuance Proposal, the ELOC Issuance Proposal and the Authorized Common Stock Increase Proposal, if there are not sufficient votes at the Special Meeting to approve and adopt the Reverse Stock Split Proposal, Series A Preferred Issuance Proposal, the ELOC Issuance Proposal and the Authorized Common Stock Increase Proposal (the “Adjournment Proposal”). The number of shares that voted for, against, and withheld from voting for this Adjournment Proposal is summarized in the table below:

 

Votes For  Votes Against  Votes Abstain  Broker Non-Votes
          
1,893,737  551,855  11,679  234,122

 

 

 

 

Exhibit No.   Description
104   Cover Page Interactive Data File (embedded with the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ASPIRE BIOPHARMA HOLDINGS, INC.
     
Dated: April 16, 2026 By: /s/ Kraig Higginson
    Kraig Higginson
    Chief Executive Officer

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Other Documents